Immunogen (IMGN) Posts Q4 Loss of 71c/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. STZ
3. APLD
4. CRGY
5. RMR
6. PEP
7. DVN
8. ANGO
9. LULU
10. SPCX

Go back to Immunogen (IMGN) Posts Q4 Loss of 71c/Share

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2015 Financial Results

July 31, 2015 6:30 AM EDT

Company Provides Corporate Update and Fiscal Year 2016 Financial Guidance

Conference Call Today at 8:00 am ET

ImmunoGens wholly owned mirvetuximab soravtansine demonstrates notable single-agent activity in early clinical testing for platinum-resistant ovarian cancer; Company plans to initiate later-stage testing this year. Events expected with other ImmunoGen product candidates in 2H2015 include initiation of clinical assessment of IMGN529 in combination with rituximab (Rituxan®) and submission of the IMGN779 IND. Events expected among partner compounds in the next 12 months include presentation of new clinical data, start of... More